X
Dear User,
On May 25, 2018, Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 (General Data Protection Regulation) came into force. We encourage you to familiarise yourself with information about the processing of personal data on the PolskieRadio.pl website.
1.The Data Administrator is Polish Radio S.A., based at 77/85 Niepodległości Ave., 00-977, Warsaw.
2.On issues regarding your data, please contact the Data Protection Officer, e-mail: iod@polskieradio.pl, tel. 22 645 34 03.
3.Personal data may be processed for marketing purposes based on consent.
4.Personal data may be shared solely for the purpose of proper implementation of services defined in the privacy policy.
5.Personal data will not be transferred outside the European Economic Area or to an international organisation.
6.Personal data will be stored for 5 years after an account is deactivated, in accordance with the law.
7.You have the right to access your personal data, correct it, to have it moved or deleted, or to limit its processing.
8.You have the right to object to further processing, and in the case of voicing consent to the processing of personal data, you have the right to withdraw your consent. The exercise of the right to withdraw consent does not affect any processing that has already taken place.
9.You have the right to lodge a complaint with the supervisory authority.
10.Polish Radio S.A. declares that no automated decisions are made when personal data is processed, and that profiling is not used.
For more information on this subject, please read our personal data and privacy policy.
I UNDERSTAND
English Section

Britain’s AstraZeneca says its COVID-19 vaccine can be 90% effective

23.11.2020 12:15
UK-based drug maker AstraZeneca said on Monday its experimental vaccine for the novel coronavirus could be around 90 percent effective without any serious side effects, news agencies reported.
A handout photo made available on November 23, 2020, showing a vial with a vaccine developed jointly by AstraZeneca and Oxford University.
A handout photo made available on November 23, 2020, showing a vial with a vaccine developed jointly by AstraZeneca and Oxford University.Photo: PAP/EPA/OXFORD UNIVERSITY/JOHN CAIRNS/HANDOUT

"This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," AstraZeneca CEO Pascal Soriot said in a statement.

"Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval,” he added.

The announcement makes AstraZeneca the latest drug producer to report positive interim data in a scientific race to curb the COVID-19 pandemic, the Reuters news agency reported.

Data published on Thursday showed that AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, with researchers expecting to release late-stage trial results by Christmas, according to a previous report by Reuters.

Poland’s prime minister said earlier this month that millions of vaccines against the coronavirus were likely to reach his country next spring as part of a European deal with drug makers.

The European Union this month struck a deal to buy up to 300 million doses of a potential coronavirus vaccine from US pharmaceutical firm Pfizer and its German partner BioNTech.

Prime Minister Mateusz Morawiecki said on Friday, November 13, that his government has set up a working group with experts from Pfizer amid efforts to make a COVID-19 vaccine available to Poles as quickly as possible.

In mid-November, Morawiecki also talked with executives from AstraZeneca as part of efforts to secure a COVID-19 vaccine for Poland, state news agency PAP has reported.

Meanwhile, US drug maker Moderna announced last Monday that its experimental vaccine was 94.5 percent effective in preventing COVID-19 based on interim data from a late-stage trial.

The European Commission on Tuesday, November 17, authorized a deal with German biotech firm CureVac to secure up to 405 million doses of its potential COVID-19 vaccine for European citizens.

EU officials have voiced hope for a deal with Moderna soon.

(gs/pk)

Source: IAR, PAP, Reuters, astrazeneca.com